Efficacy and safety of nesiritide in patients with acute decompensated heart failure

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 2, 2010, Pages 159-169

  Dewald, Tracy A ^a   Hernandez, Adrian F ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

heart failure; natriuretic peptides; vasodilators

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; AMRINONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CORTICOTROPIN; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE ACTIVATOR; INOTROPIC AGENT; ISTAROXIME; LEVOSIMENDAN; LOOP DIURETIC AGENT; MILRINONE; NESIRITIDE; PLACEBO; URODILATIN; VASODILATOR AGENT; VASOPRESSIN; VASOPRESSIN ANTAGONIST; NATRIURETIC FACTOR;

ABDOMINAL PAIN; ACUTE DECOMPENSATED HEART FAILURE; ACUTE HEART FAILURE; ANGINA PECTORIS; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME INHIBITION; FATIGUE; HEART HEMODYNAMICS; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HORMONE INHIBITION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; NAUSEA; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TACHYCARDIA; TREATMENT OUTCOME; VASODILATATION; ACUTE DISEASE; HEART FAILURE; MORTALITY;

ACUTE DISEASE; HEART FAILURE; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; VASODILATOR AGENTS;

EID: 77951911490     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.173     Document Type: Review

References (53)

1. Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), e25-e146 (2008).
2. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 83(5), 596-602 (2000).
3. Krumholz HM, Wang Y, Mattera JA et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation 113(13), 1683-1692 (2006).
4. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur. J. Heart. Fail. 4(3), 361-371 (2002).
5. Adams KF Jr, Fonarow GC, Emerman CL et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart. J. 149(2), 209-216 (2005).
6. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293(5), 572-580 (2005).
7. Nieminen MS, Brutsaert D, Dickstein K et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur. Heart. J. 27(22), 2725-2736 (2006).
8. Kosiborod M, Lichtman JH, Heidenreich PA et al. National trends in outcomes among elderly patients with heart failure. Am. J. Med. 119(7), e1-e7 (2006).
9. Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113(6), e85-e151 (2006).
10. Jessup M, Abraham WT, Casey DE et al.; 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 53, 1343-1382 (2009).
11. Felker GM, Adams KF Jr, Konstam MA, O'Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am. Heart. J. 145(2 Suppl.), S18-S25 (2003).
12. Lucas C, Johnson W, Hamilton MA et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am. Heart. J. 140(6), 840-847 (2000).
13. Adamson PB, Magalski A, Braunschweig F et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J. Am. Coll. Cardiol. 41(4), 565-571 (2003).
14. Heart Failure Society of America. Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J. Card. Fail. 12(1), 10-38 (2006).
15. Ramírez A, Abelmann WH. Cardiac decompensation. N. Engl. J. Med. 290(9), 499-501 (1974).
16. O'Connor CM, Gattis WA, Uretsky BF et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart. J. 138(1 Pt 1), 78-86 (1999).
17. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and the risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100(12), 1311-1315 (1999).
18. Cuffe MS, Califf RM, Adams KF et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287(12), 1541-1547 (2002).
19. Costanzo MR, Johannes RS, Pine M et al. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure national Registry (ADHERE) database. Am. Heart J. 154, 267-277 (2007).
20. Dickstein K, Cohen-Solal A, Filippatos G et al. European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 29, 2388-2442 (2008).
21. Natrecor® (nesiritide), prescribing information. Scios, Inc., Fremont, CA, USA (2005).
22. Takahashi T, Allen PD, Izumo S. Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca2+ ATPase gene. Circ. Res. 71(1), 9-17 (1992).
23. Suzuki T, Yamazaki T, Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc. Res. 51(3), 489-494 (2001).
24. Chen HH. Heart Failure. A state of brain natriuretic peptide deficiency or resistance or both. J. Am. Coll. Cardiol. 49(10), 1089-1091 (2007).
25. Mills RM, LeJemtel TH, Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J. Am. Coll. Cardiol. 34(1), 155-162 (1999).
26. Burger AJ. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest. Heart Fail. 11(1), 30-38 (2005).
27. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. 76(1), 91-96 (1993).
28. La Villa G, Fronzaroli C, Lazzeri C et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J. Clin. Endocrinol. Metab. 78(5), 1166-1171 (1994).
29. Jensen KT, Eiskjaer H, Carstens J, Pedersen EB. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin. Sci. (Lond.) 96(1), 5-15 (1999).
30. Yoshimura M, Yasue H, Morita E et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusions in patients with congestive heart failure. Circulation 84(4), 1581-1588 (1991).
31. Wang DJ, Dowling TC, Meadows D et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110(12), 1620-1625 (2004).
32. Hobbs RE, Mills RM. Therapeutic potential of nesiritide (recombinant B-type natriuretic peptide) in the treatment of heart failure. Expert Opin. Investig. Drugs 8(7), 1063-1072 (1999).
33. Witteles RM, Kao D, Christopherson D et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction: a randomized, double-blind, placebo-controlled clinical trial. J. Am. Coll. Cardiol. 50(19), 1835-1840 (2007).
34. Butler J, Emerman C, Peacock WF, Mathur VS, Young JB. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol. Dial. Transplant. 19(2), 391-399 (2004).
35. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111(12), 1487-1491 (2005).
36. Iglesias J, Hom D, Antoniotti M, Ayoub S, Levine JS. Predictors of worsening renal function in adult patients with congestive heart failure receiving recombinant human B-type brain natriuretic peptide (nesiritide). Nephrol. Dial. Transplant. 21(12), 3458-3465 (2006).
37. Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N. Engl. J. Med. 343(4), 246-253 (2000).
38. Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart. J. 144(6), 1102-1108 (2002).
39. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287(12), 1531-1540 (2002).
40. Peacock WF IV, Holland R, Gyarmathy R et al. Observation unit treatment of heart failure with nesiritide: results from the PROACTION trial. J. Emerg. Med. 29(3), 243-252 (2005).
41. Peacock WF IV. Initial results from the PROACTION study. J. Emerg. Med. 31(4), 435-436 (2006).
42. Yancy CW, Saltzberg MT, Berkowitz RL et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I Trial). Am. J. Cardiol. 94, 595-601 (2004).
43. Yancy CW, Sing A. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the follow-up serial infusions of nesiritide [FUSION I] Trial). Am. J. Cardiol. 98, 226-229 (2006).
44. Yancy CW, Krum H, Massie BM et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure. Results of the second follow-up serial infusions of nesiritide (FUSION II) Trial. Circ. Heart Fail. 1, 9-16 (2008).
45. Jefferies JL, Price JF, Denfield SW et al. Safety and efficacy of nesiritide in pediatric heart failure. J. Card. Fail. 13(7), 541-548 (2007).
46. Mahle WT, Cuadrado AR, Kirshbom PM, Kanter KR, Simsic JM. Nesiritide in infants and children with congestive heart failure. Pediatr. Crit. Care. Med. 6(5), 543-546 (2005).
47. Mentzer RM Jr, Oz MC, Sladen RN et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J. Am. Coll. Cardiol. 49(6), 716-726 (2007).
48. Beaver TM, Winterstein AG, Shuster JJ et al. Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery. Clin. Cardiol. 29(1), 18-24 (2006).
49. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293(15), 1900-1905 (2005).
50. Al-Ahmad A, Rand WM, Manjunath G et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 38(4), 955-962 (2001).
51. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109(8), 1004-1009 (2004).
52. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 35(3), 681-689 (2000).
53. Scios Inc. Dear Healthcare Provider letter. Panel of Cardiology Experts Provides Recommendations to Scios Regarding NATRECOR® . 13, 1-8 July (2005).